Correction: Oncol Ther https://doi.org/10.1007/s40487-023-00251-6 In this article the authors erroneously mentioned the drug repotrectinib in the introduction of the paper. This should be replaced with the drug entrectinib. The original article has been corrected.
Correction: Repotrectinib’s Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer (Oncology and Therapy, (2024), 12, 1, (163-171), 10.1007/s40487-023-00251-6)
Metro G.;Gariazzo E.;Costabile S.;Baglivo S.;Roila F.;Colamartini F.;Palumbo B.;Marcomigni L.;
2024
Abstract
Correction: Oncol Ther https://doi.org/10.1007/s40487-023-00251-6 In this article the authors erroneously mentioned the drug repotrectinib in the introduction of the paper. This should be replaced with the drug entrectinib. The original article has been corrected.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
